KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Net Cash Flow (2016 - 2025)

Globus Medical (GMED) has disclosed Net Cash Flow for 15 consecutive years, with $150.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 9.4% year-over-year to $150.4 million, compared with a TTM value of -$280.7 million through Dec 2025, down 188.59%, and an annual FY2025 reading of -$280.7 million, down 188.59% over the prior year.
  • Net Cash Flow was $150.4 million for Q4 2025 at Globus Medical, up from $141.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $208.3 million in Q3 2024 and bottomed at -$326.7 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $13.2 million, with a median of $44.7 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 7584.31% in 2021, while the deepest fall reached 1341.24% in 2021.
  • Year by year, Net Cash Flow stood at -$168.6 million in 2021, then surged by 110.13% to $17.1 million in 2022, then surged by 1000.68% to $188.0 million in 2023, then decreased by 11.74% to $166.0 million in 2024, then fell by 9.4% to $150.4 million in 2025.
  • Business Quant data shows Net Cash Flow for GMED at $150.4 million in Q4 2025, $141.8 million in Q3 2025, and -$246.2 million in Q2 2025.